Jcog1113

Author: vumr

August undefined, 2024

WebA Phase II selection design trial was conducted to identify the most promising regimen for comparison with standard therapy in chemo-naive patients with unresectable or recurrent biliary tract cancer (JCOG0805). Gemcitabine plus S-1 therapy showed better efficacy than S-1 monotherapy with acceptable … WebThe JCOG1113 study suggested that gemcitabine plus S-1 (GS) had noninferior median overall survival and comparable incidence of significant neutropenia as compared to GC treatments. This study evaluates the efficacy and safety of a modified GS regimen.

UMIN Clinical Trials Registry

WebDISCLAIMER: The appearance of hyperlinks does not constitute endorsement by the 413th Flight Test Group, the U.S. Air Force Reserve, or the Department of Defense, of the external Web site, or the information, products or services contained therein. Web1 feb 2024 · 419 Background: JCOG1113 (UMIN000001685) is a randomized phase III trial in patients (pts) with advanced biliary tract cancers (BTCs) that shows the non-inferiority of gemcitabine plus S-1 (GS) to ... dentist of hudson oaks

Radical resection of an initially unresectable intrahepatic ...

Web19 gen 2024 · Between May 8, 2013 and March 4, 2016, a total of 354 patients were enrolled to JCOG1113; 175 were assigned to the GC arm and 179 to the GS arm. For this subgroup analysis to investigate the influence of age, all registered patients of JCOG1113 were stratified by age; < 75 (non-elderly group) and ≥ 75 years (elderly group). Web18 giu 2024 · JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). Web1 dic 2024 · The median PFS was 5.8 months with GC and 6.8 months with GS (HR 0.86; 95% CI 0.70-1.07). The RR was 32.4% with GC and 29.8% with GS. Both treatments were generally well-tolerated. Clinically significant AEs were observed in 35.1% of patients in the GC arm and 29.9% in the GS arm. ffxiv weathered gear dyable

胆道癌 FUGA‐BT（JCOG1113）臨床試験サマリ OncoTribune

413th Flight Test Group > Home - AF

Web19 gen 2024 · Patient characteristics. Of all registered 354 patients in JCOG1113, 60 patients aged ≥ 75 years were classified into the elderly group (20 in GC arm and 40 in GS arm), and 294 patients aged ... WebA phase II study, JCOG0805 showed that gemcitabine plus S-1 was more promising than S-1 alone in ABTC, and a recently phase III JCOG1113 (FUGA-BT) showed gemcitabine plus S-1 (GS) is non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) benefit. ffxiv weathered evenstar hatWeb22 gen 2024 · January 20th 2024. Results from the phase 2 Talem trial, presented at the 2024 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with … dentist of grossmont

"http://www.jcog.jp/document/1113.pdf " - Jcog1113

Jcog1113

Efficacy and safety of S-1 following gemcitabine with cisplatin for ...

WebJCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). Web23 nov 2024 · Realty Hub. See more homes for sale in. Gulfport. Take a look. 5413 11th Ave S, Gulfport, FL 33707 is a 3 bedroom, 1 bathroom, 900 sqft single-family home built in 1955. This property is not currently available for sale. 5413 11th Ave S was last sold on Nov 23, 2024 for $309,000. The current Trulia Estimate for 5413 11th Ave S is $248,100. Sold.

Did you know?

Web19 gen 2024 · In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 3 … WebIn JCOG1113, GS showed non-inferiority to GC in overall survival (OS) with good tolerance (median OS: 13.4 months with GC and 15.1 months with GS, hazard ratio 0.945; 90% condence interval 0.78 ...

Web24 nov 2024 · A phase II study, JCOG0805 showed that gemcitabine plus S-1 was more promising than S-1 alone in ABTC, and a recently reported phase III JCOG1113 showed gemcitabine plus S-1 (GS) is non-inferiority to gemcitabine plus cisplatin (GC) in … WebJCOG1113 (UMIN000010667) showed the non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in terms of overall survival (OS) in patients (pts) with advanced BTCs. We aimed to compare clinical features among the primary sites of BTCs using JCOG1113 data. Methods: Among the 354 pts enrolled in JCOG1113, 352 pts were …

Web19 gen 2024 · 419. Background: JCOG1113 (UMIN000001685) is a randomized phase III trial in patients (pts) with advanced biliary tract cancers (BTCs) that shows the non-inferiority of gemcitabine plus S-1 (GS) to gemcitabine plus cisplatin (GC) regarding overall survival (OS). Previous reports suggest that a history of major hepatectomy (MH) may affect … WebThe oral fluoropyrimidine, S-1, combined with or without gemcitabine is considered to be a promising agent for treating advanced biliary tract cancer; gemcitabine plus cisplatin is the current standard regimen. This randomized phase II trial was designed to evaluate the safety and efficacy of two re …

Web24 gen 2024 · JCOG1113 (UMIN000010667) showed the non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in terms of overall survival (OS) in patients (pts) with advanced BTCs. We aimed to compare clinical features among the primary sites of BTCs using JCOG1113 data.

Web1 dic 2024 · Introduction. Biliary tract cancers (BTCs), including cancers of the intrahepatic bile duct (IHBD), extrahepatic bile duct (EHBD), gallbladder (GB), and ampulla of Vater (AV), are relatively rare [1].BTC is often diagnosed at an advanced stage, and early postoperative recurrence is frequent, even in patients with resectable disease [2].The prognoses of … dentist of metairieWebView detailed information about property 1613 County Road 5411, Oark, AR 72852 including listing details, property photos, school and neighborhood data, and much more. dentist of greeley coWebIn JCOG1113, GS showed non-inferiority to GC in overall survival (OS) with good tolerance (median OS: 13.4 months with GC and 15.1 months with GS, hazard ratio 0.945; 90% condence interval 0.78 ... dentist of lake worthWeb10 mag 2024 · Gemcitabine combined with platinum/fluorouracil drugs is the standard first-line treatment for advanced biliary tract cancers (BTCs). We explored the safety and efficacy of toripalimab plus gemcitabine and S-1 (GS) as the first-line treatment for advanced BTCs. At a one-sided significance level of 0.025, a total of 50 patients could provide 80% power … ffxiv weathered gear upgradeWeb29 gen 2024 · 368 Background: JCOG1113 is a randomized phase III trial to evaluate gemcitabine (GEM) plus S-1 (GS) versus GEM plus cisplatin (GC) regarding overall survival (OS) for advanced biliary tract cancer (BTC) (UMIN000001685) and the non-inferiority of GS was demonstrated. It is necessary to consider renal function using cisplatin or S-1 … dentist of ontario ranchWebCC-13 JOINT LEGAL CUSTODY ATTACHMENT TO Petition Response Request for Order Responsive Declaration to Request for Order Stipulation and Order for Custody and/or Visitation of Children Findings and Order After Hearing or Judgment dentist of metairie reviewsWebRandomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113, FUGA-BT) Date of disclosure of the study information: 2013/05/08: Last modified on: 2024/01/05 13:46:57 dentist of hyde park ohio